SNDX
Syndax Pharmaceuticals Inc
18.10$
+2.6%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | |
| – | 3,368.3% | 3,417.8% | 3,035.4% | 0.0% | – | – | 0.3% | 0.4% | – | 3.5% | 4.0% | |
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -0.4% | – | 96.5% | 96.0% | |
| – | 1,523.0% | 2,595.5% | 2,286.6% | 3,962.2% | 2,834.1% | 3,324.7% | 63.2% | 93.6% | – | 1,020.5% | 150.1% | |
| – | 1,848.6% | 1,091.9% | 752.4% | 1,139.6% | 1,058.8% | 1,483.5% | 18.1% | 26.3% | – | 510.5% | 104.3% | |
| – | 3,371.6% | 3,687.4% | 3,039.0% | 5,101.7% | 3,892.9% | 4,808.2% | 81.2% | 119.9% | – | 1,530.9% | 254.4% | |
| – | -3,271.6% | -3,587.4% | -2,939.0% | -5,001.7% | -3,792.9% | -4,708.2% | 18.8% | -119.9% | – | -1,434.4% | -158.4% | |
| – | 251.2% | 78.4% | 67.4% | 128.0% | 103.6% | 155.4% | 1.4% | 2.5% | – | 20.8% | 19.6% | |
| – | -3,846.7% | -3,645.2% | -2,884.3% | -4,875.5% | -3,694.6% | -4,822.5% | 17.8% | -118.0% | – | -1,346.1% | -165.6% | |
| – | 245.3% | -7.3% | -3.6% | 126.2% | -6.1% | -5.9% | 0.0% | -4.4% | – | -1,346.1% | – | |
| – | -3,846.7% | -3,645.2% | -2,884.3% | -4,875.5% | -3,688.5% | -4,816.7% | 17.8% | -113.6% | – | -1,346.1% | -165.6% | |
| – | -3,268.3% | -3,580.1% | -2,935.4% | -4,996.6% | -3,786.9% | -4,702.3% | 18.8% | -119.9% | – | -1,325.3% | -146.0% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.